Table 3

Univariate Poisson regression analysis per age group

 Group <40Group ≥40<55Group ≥55
RR (95% CI)RR (95% CI)RR (95% CI)
Baseline smoking0.83 (0.16 to 4.23)1.18 (0.60 to 2.32)2.00 (1.11 to 3.58)
 BMI<25RefRefRef
 BMI>25<300.91 (0.22 to 3.82)0.58 (0.37 to 1.50)1.12 (0.58 to 2.14)
 BMI>300.28 (0.05 to 1.66)0.74 (0.19 to 1.73)1.19 (0.50 to 2.87)
 Ritchie Articular Index1.00 (0.94 to 1.06)0.95 (0.89 to 1.01)0.98 (0.93 to 1.03)
 Swollen joint count1.11 (1.02 to 1.21)0.97 (0.93 to 1.01)1.01 (0.98 to 1.05)
 JSN1.17 (1.01 to 1.35)1.06 (0.99 to 1.14)1.00 (0.94 to 1.07)
 Erosions1.13 (0.90 to 1.41)1.06 (1.01 to 1.12)1.02 (0.89 to 1.15)
RF−/ACPA−RefRefRef
RF+/ACPA−1.65 (0.28 to 9.82)3.31 (0.93 to 11.75)1.47 (0.48 to 4.47)
RF−/ACPA+2.78 (0.48 to 16.15)1.76 (0.54 to 5.79)2.52 (0.84 to 7.54)
RF+/ACPA+5.39 (1.25 to 23.15)3.41 (1.33 to 8.71)4.19 (1.58 to 11.07)
RF−RefRefRef
RF+2.81 (0.90 to 8.77)2.88 (1.40 to 5.96)2.63 (1.31 to 5.28)
ACPA−RefRefRef
ACPA+3.79 (1.21 to 11.89)2.02 (0.94 to 4.33)3.39 (1.58 to 7.28)
Average ESR over time1.04 (1.00 to 1.08)1.02 (1.00 to 1.04)1.02 (1.01 to 1.03)
Sequential monotherapyRefRefRef
Step up to combination therapy0.44 (0.07 to 2.79)1.29 (0.56 to 3.02)0.81 (0.34 to 1.93)
Initial combination therapy with prednisone0.89 (0.20 to 3.93)0.77 (0.36 to 1.64)0.93 (0.38 to 2.25)
Initial combination therapy with infliximab0.20 (0.04 to 0.95)0.49 (0.19 to 1.27)0.84 (0.36 to 2.00)
  • Bold typeface represents risk factors that attained significance. 95% CI, 98.33% (Bonferroni correction) CI; ACPA, anticitrullinated protein antibodies; BMI, body mass index; Erosions, erosion score (SHS); ESR, erythrocyte sedimentation rate; JSN, joint space narrowing; RF, rheumatoid factor; RR, relative risk; SHS, Sharp/van der Heijde score.